Back to search
FDAFDA · Food and drugs·Recall number D-0203-2021

neostigmine methylsulfate 5 mg/5 mL, (1mg/ml), Rx Only, 5 mL Single Dose Syringe, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT, 06095, barcode 70004075009

Published January 13, 2021 · Recall initiated: December 17, 2020

Summary

FDA records drug Class II recall D-0203-2021, published January 13, 2021 and initiated December 17, 2020. Recalling firm: SCA Pharmaceuticals; Status: Terminated; Reported quantity: 390 syringes; Lot: Lot # 1220023044, BUD 1/30/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
SCA Pharmaceuticals
Distributor
Product was distributed to hospitals nationwide.
Lot
Lot # 1220023044, BUD 1/30/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was neostigmine methylsulfate 5 mg/5 mL, (1mg/ml), Rx Only, 5 mL Single Dose Syringe, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT, 06095, barcode 70004075009 recalled?

Yes. FDA published recall D-0203-2021 on January 13, 2021. Reported hazard: Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit

What should I do if I have this product?

Voluntary: Firm initiated · Letter